×
Plus Therapeutics Common Stock Net 2010-2025 | PSTV
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Plus Therapeutics common stock net from 2010 to 2025. Common stock net can be defined as the value of common equity ownership.
View More
Plus Therapeutics Common Stock Net 2010-2025 | PSTV
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Plus Therapeutics common stock net from 2010 to 2025. Common stock net can be defined as the value of common equity ownership.
Related Stocks
Company Name
Market
Cap
Chugai Pharmaceutical (CHGCY)
$80.2B
Zoetis (ZTS)
$68.3B
Daiichi Sankyo, - (DSNKY)
$47.1B
Takeda Pharmaceutical (TAK)
$46.9B
BeOne Medicines - (ONC)
$32.3B
Sandoz Group AG (SDZNY)
$26.4B
Summit Therapeutics (SMMT)
$20.8B
Merck (MKKGY)
$17.3B
Shionogi (SGIOY)
$14.5B
United Therapeutics (UTHR)
$13.8B
Neurocrine Biosciences (NBIX)
$13.2B
Orion OYJ (ORINY)
$11.7B
IPSEN (IPSEY)
$10.9B
Stevanato Group S.p.A (STVN)
$7.7B
Corcept Therapeutics (CORT)
$7.3B
Madrigal Pharmaceuticals (MDGL)
$6.8B
Grifols, S.A (GRFS)
$6.8B
Ionis Pharmaceuticals (IONS)
$6.7B
Hikma Pharmaceuticals Plc (HKMPF)
$5.9B
Ono Pharmaceutical (OPHLF)
$5.2B
Soleno Therapeutics (SLNO)
$4.4B
Hypermarcas (HYPMY)
$3.1B
Crinetics Pharmaceuticals (CRNX)
$2.9B
NewAmsterdam Pharma (NAMS)
$2.7B
Catalyst Pharmaceuticals (CPRX)
$2.6B
Procaps Group, S.A (PROCF)
$2.5B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$2.5B
Centessa Pharmaceuticals (CNTA)
$2.1B
Ocular Therapeutix (OCUL)
$1.9B
BioCryst Pharmaceuticals (BCRX)
$1.8B